Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of ACT001 in Children and Adolescents With Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

NCT06838676 is registered in ClinicalTrials.gov with Nationwide Children's Hospital as lead sponsor.

NCT NCT06838676
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06838676 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of ACT001 in Children and Adolescents With Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
Lead sponsor
Nationwide Children's Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
July 10, 2025
Completion date
July 31, 2035
Enrollment
60 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse intrinsic pontine gliomas (dipg), h3k27-altered high grade glioma, progressive dipg, recurrent dipg, refractory dipg